News
MSD splits pharma business, hiving off oncology
MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
News
FDA maps new regulatory route for ultra-rare diseases
The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.
R&D
Why the government’s latest funding push is critical to the ...
Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
News
Gilead buys cell therapy partner Arcellx for up to $7.8bn
Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.
News
Head-to-head trial dents Novo Nordisk's obesity hopes
Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
